Review of Cancer Screening Investigations in New Diagnoses of Idiopathic Inflammatory Myopathies at a Single Tertiary Hospital

Bradhurst, Peter; Limaye, Sandhya; Kane, Barry

doi:10.1097/rhu.0000000000001636

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These recommendations are based on expert opinion only; no study has empirically investigated the utility of the timing and frequency of these specific panels of basic and enhanced cancer screening and hence the inability to ascribe an evidence quality grade. A growing body of evidence demonstrates the utility of 18 F-FDG PET-CT as a screening modality for IIM-associated cancer [33][34][35][36][37] . The Expert Group deemed it appropriate to form a conditional recommendation relating to the use of 18 F-FDG PET-CT scanning as a screening method only in those with a 'high' risk of cancer when 'basic' and 'enhanced' screening panels have not identified a cancer, especially if lymphoma is suspected.…”

Section: Evidence-based Guidelinesmentioning

confidence: 99%

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

Oldroyd,

Callen,

Chinoy

et al. 2023

Nat Rev Rheumatol

View full text Add to dashboard Cite

Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence-and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient's IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a 'basic' screening panel (including chest radiography and preliminary laboratory tests) and an 'enhanced' screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18 F-FDG PET-CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.Sections feedback on the acceptability of the final recommendations and co-authored the final manuscript, although they were not involved in the voting process (one patient partner chose to remain anonymous and not be included as a co-author).The project and final manuscript were reviewed and approved by the IMACS Scientific Committee.Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

show abstract